Category: Corporate NewsBy adminApril 28, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda issues statement regarding the “Stay Home to Protect your Family and Community” initiativeNextNext post:Summary of AGM Decisions – 10 May 2020Related PostsEarning Release One Pager 2Q24August 13, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024Rameda 4Q23 Earnings ReleaseMarch 20, 2024Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023Rameda Reports its 3Q23 ResultsNovember 14, 2023
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioNovember 28, 2023
